Evotec's Licensing Pivot and Basel Showcase Mark a Defining Moment for the Turnaround

Evotec finds itself in a curious double act. The Hamburg-based drug discovery specialist is rolling out an ambitious, capital-light licensing product called J.TRAIN that could reshape its Biologics business, while simultaneously flying the flag for its scientific foundations at a European conference in Basel. For investors watching the stock hover at exactly €5.00, the interplay between these two narratives will determine whether the shares can extend their recovery from the year’s low of €4.02. Even with that bounce, the stock remains nearly 10% in the red since January.

J.TRAIN bundles modular clean rooms with full process automation, allowing biopharma companies to install Evotec’s proprietary manufacturing technology inside their own factories. The twist is the business model: the Just–Evotec Biologics unit is shifting from building and running its own capacity to licensing out the technology and accompanying process design. The obvious question for shareholders is whether that generates enough recurring revenue, or whether Evotec is handing over its crown jewels too cheaply and too soon.

A deal with Sandoz last December already validated the concept, and regulators including the FDA are pushing for continuous manufacturing, which is seen as cheaper and more efficient than batch processing. If the licensing model scales, the Biologics division could be worth well over €1bn, according to activist investor MAK Capital. The hedge fund, which holds roughly 7% of Evotec, is agitating for a rapid spin-off of the unit — a valuation that already outstrips the entire group’s current market capitalisation. The supervisory board is running a strategic review with the help of Morgan Stanley and Moelis & Company.

On the cost side, the Horizon restructuring programme is targeting annual savings of €75m by the end of 2027. The company is already booking provisions in the high double-digit millions for severance and impairments as it pares global operating sites down to ten. Restructuring costs are expected to total around €100m between 2026 and 2028.

Should investors sell immediately? Or is it worth buying Evotec?

Yet the financial numbers for early 2026 paint a stark picture. Group revenue slid to €156.6m in the first quarter, while adjusted EBITDA sank to minus €21.9m. The Biologics segment, the intended growth engine, generated just €36.8m of that revenue — a drop triggered by the absence of a large Sandoz licensing payment that flattered the prior-year comparison. Its adjusted EBITDA swung to minus €12.1m. The net loss widened to €121.9m. Cash and equivalents stood at €444.8m at the end of March.

Management’s full-year guidance leaves little margin for error: revenue in a range of €700m to €780m, and adjusted EBITDA at best €40m. The J.TRAIN model’s success is baked into those numbers, but the risk of cannibalising Evotec’s own Seattle manufacturing plant is real. If partners opt to build their own factories, the demand for Evotec’s existing capacity could fade.

Amidst this operational turbulence, the company’s scientific team took the stage at the 16th European ISSX meeting in Basel. Phil Butler, an Evotec manager, presented on DMPK workflows for diverse therapeutic modalities, and a poster detailed the use of chemical inhibitors to determine specific enzyme fractions. DMPK and ADME are the bedrock of preclinical development — they do not generate quick revenue but reinforce the platform’s credibility. The conference also touched on artificial intelligence and machine learning for bridging laboratory discovery to clinical application. No new partnerships or orders emerged, but the appearance serves as a soft signal that Evotec’s technical engine is still running while the financial restructuring grinds on.

Evotec at a turning point? This analysis reveals what investors need to know now.

Technically, the stock is treading water. It sits exactly on its 50-day moving average, and the relative strength index of 55.8 points to a perfectly neutral market. The next major catalyst is the first-half results, due in early August. The Biologics segment will need to show organic growth, and if margins turn positive, the strategic review could gain momentum. A first J.TRAIN contract would amplify any spin-off signal. If the recovery fails to materialise, MAK Capital is likely to escalate its campaign, putting the very rationale for Evotec as an integrated company on the line.

For now, Evotec is balancing a licensing gamble with hard-nosed cost-cutting and a quiet defence of its scientific credentials. The Basel showcase buys time and credibility, but the real test will come when the numbers for the first half of 2026 land on investors’ desks.

Ad

Evotec Stock: New Analysis - 30 June

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...

en | DE0005664809 | EVOTECS | boerse | 69662641 |